Pharma Journalist -

Eli Lilly and Company has agreed to acquire Ventyx Biosciences in an all-cash transaction valued at approximately $1.2 billion, strengthening Lilly’s pipeline in inflammation-driven…
Read More...

Day One Biopharmaceuticals has completed its acquisition of Mersana Therapeutics, marking a significant expansion of its oncology pipeline and reinforcing its strategy to advance…
Read More...

Protara Therapeutics, Inc., a clinical-stage biotechnology company focused on cancer and rare diseases, has received multiple regulatory boosts from the U.S. Food and Drug…
Read More...

China’s drug regulator has expanded treatment options for patients with rare, genetically driven cancers by approving Zai Lab Limited’s AUGTYRO™ (repotrectinib) for adult patients with…
Read More...

Outlook Therapeutics has received a setback in its efforts to bring an FDA-approved bevacizumab treatment for retinal disease to the U.S. market. The company announced that the U.S.…
Read More...

Samsung Bioepis has started direct commercialization of BYOOVIZ, a biosimilar to Lucentis (ranibizumab), across Europe, marking a significant shift in the company’s regional strategy.…
Read More...

Eisai and Biogen have reached a new regulatory milestone in China with the acceptance of a Biologics License Application (BLA) for the subcutaneous formulation of LEQEMBI (lecanemab) by…
Read More...

Insilico Medicine, a global artificial intelligence (AI)–driven drug discovery company, has entered into a multi-year research and development collaboration with Servier, an independent…
Read More...

The US Food and Drug Administration (FDA) has accepted for priority review a supplemental biologic license application (sBLA) for Tzield (teplizumab-mzwv), a therapy designed to delay…
Read More...

Takeda and Protagonist Therapeutics have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults…
Read More...